Announcement • Apr 30
Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, May 27, 2026 Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, May 27, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Qianjiang, Hubei China Reported Earnings • Apr 17
Full year 2025 earnings released: EPS: CN¥0.078 (vs CN¥0.21 in FY 2024) Full year 2025 results: EPS: CN¥0.078 (down from CN¥0.21 in FY 2024). Revenue: CN¥783.2m (down 6.6% from FY 2024). Net income: CN¥22.5m (down 64% from FY 2024). Profit margin: 2.9% (down from 7.4% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • Mar 31
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Dec 31
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 17, 2026 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 17, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.045 (vs CN¥0.032 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.045 (up from CN¥0.032 in 3Q 2024). Revenue: CN¥209.8m (up 8.7% from 3Q 2024). Net income: CN¥13.0m (up 39% from 3Q 2024). Profit margin: 6.2% (up from 4.9% in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Announcement • Sep 25
Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) signed share transfer agreement to acquire remaining 49.2% stake in Hubei Ling'an Technology Co., Ltd. from Zhang Yong, Xia Changpei and Dai Liang for CNY 27 million. Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) signed share transfer agreement to acquire remaining 49.2% stake in Hubei Ling'an Technology Co., Ltd. from Zhang Yong, Xia Changpei and Dai Liang for CNY 27 million on September 24, 2025. A cash consideration of CNY 27 million will be paid by Qianjiang Yongan Pharmaceutical Co., Ltd. Zhang Yong will sell 39.75% stake, Xia Changpei will sell 6.80% stake, and Dai Liang will sell 2.65% stake. Upon completion, Qianjiang Yongan Pharmaceutical Co., Ltd. will own 100% stake in Hubei Ling'an Technology Co., Ltd.
As of July 31, 2025, Hubei Ling'an Technology Co., Ltd. reported total assets of CNY 164.11 million and total common equity of CNY 87.47 million.
The transaction has been approved by the board of Qianjiang Yongan Pharmaceutical Co., Ltd. Declared Dividend • Jul 07
Dividend of CN¥0.10 announced Dividend of CN¥0.10 is the same as last year. Ex-date: 9th July 2025 Payment date: 9th July 2025 Dividend yield will be 0.3%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is not covered by earnings (102% earnings payout ratio) nor is it adequately covered by cash flows (95% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 13% to bring the payout ratio under control. However, EPS has declined by 20% over the last 5 years so the company would need to reverse this trend. Announcement • Jul 02
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • Apr 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.8% average weekly change). Announcement • Apr 29
Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025 Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025, at 14:00 China Standard Time. Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥11.25, the stock trades at a trailing P/E ratio of 52.7x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total returns to shareholders of 1.1% over the past three years. Reported Earnings • Apr 11
Full year 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.042 loss in FY 2023) Full year 2024 results: EPS: CN¥0.21 (up from CN¥0.042 loss in FY 2023). Revenue: CN¥838.8m (down 14% from FY 2023). Net income: CN¥61.8m (up CN¥74.1m from FY 2023). Profit margin: 7.4% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Announcement • Apr 11
Qianjiang Yongan Pharmaceutical Co., Ltd. Proposes the Final Cash Dividend for the Year 2024 Qianjiang Yongan Pharmaceutical Co., Ltd. proposed the final Cash dividend/10 shares (tax included) of CNY 1.0000000 for the year 2024. Announcement • Mar 31
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 31
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 10, 2025 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 10, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.034 loss in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.032 (up from CN¥0.034 loss in 3Q 2023). Revenue: CN¥192.9m (down 14% from 3Q 2023). Net income: CN¥9.37m (up CN¥19.1m from 3Q 2023). Profit margin: 4.9% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.14 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.081 (down from CN¥0.14 in 2Q 2023). Revenue: CN¥229.2m (down 14% from 2Q 2023). Net income: CN¥23.8m (down 42% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Chairman of the Supervisory Board Wu Yuxi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Jun 29
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • May 24
Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024 Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Qianjiang, Hubei China Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.097 (vs CN¥0.051 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.097 (up from CN¥0.051 in 1Q 2023). Revenue: CN¥196.6m (down 37% from 1Q 2023). Net income: CN¥28.7m (up 91% from 1Q 2023). Profit margin: 15% (up from 4.8% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 20
Full year 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.48 profit in FY 2022) Full year 2023 results: CN¥0.042 loss per share (down from CN¥0.48 profit in FY 2022). Revenue: CN¥972.9m (down 34% from FY 2022). Net loss: CN¥12.3m (down 109% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥6.38, the stock trades at a trailing P/E ratio of 75.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 28% over the past three years. Announcement • Mar 30
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to CN¥6.20, the stock trades at a trailing P/E ratio of 73.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in China. Total loss to shareholders of 26% over the past three years. Announcement • Dec 30
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 19, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.15 profit in 3Q 2022) Third quarter 2023 results: CN¥0.034 loss per share (down from CN¥0.15 profit in 3Q 2022). Revenue: CN¥224.4m (down 24% from 3Q 2022). Net loss: CN¥9.70m (down 122% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 2% per year. New Risk • Aug 24
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.6% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.6% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.6% net profit margin). Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: CN¥0.48 (vs CN¥0.38 in FY 2021) Full year 2022 results: EPS: CN¥0.48 (up from CN¥0.38 in FY 2021). Revenue: CN¥1.46b (down 6.6% from FY 2021). Net income: CN¥140.3m (up 30% from FY 2021). Profit margin: 9.6% (up from 6.9% in FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.13 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.13 in 3Q 2021). Revenue: CN¥296.2m (down 28% from 3Q 2021). Net income: CN¥45.1m (up 28% from 3Q 2021). Profit margin: 15% (up from 8.5% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.13 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.24 (up from CN¥0.13 in 2Q 2021). Revenue: CN¥414.7m (up 4.0% from 2Q 2021). Net income: CN¥66.0m (up 68% from 2Q 2021). Profit margin: 16% (up from 9.9% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 11% per year. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improved over the past week After last week's 27% share price gain to CN¥15.32, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 48% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Wang Yonghai was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.07 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥413.2m (up 33% from 3Q 2020). Net income: CN¥35.2m (up 70% from 3Q 2020). Profit margin: 8.5% (up from 6.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 29
Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥398.8m (up 9.9% from 2Q 2020). Net income: CN¥39.4m (down 56% from 2Q 2020). Profit margin: 9.9% (down from 25% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Announcement • Jun 12
Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership). Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) signed an agreement to acquire a 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership) for CNY 70 million on April 30, 2021. Under the term, Qianjiang Yongan Pharmaceutical Co., Ltd. will pay CNY 32.69 million and CNY 27.31 million to Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership) within 10 days from the date when Wuhan Low-dimensional Materials Research Institute Co., Ltd. completes the capital increase and industrial and commercial change and the remaining CNY 5.45 million and CNY 4.55 million to Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership) within 10 days after the completion of the industrial and commercial change of this equity transfer respectively. In related transaction, Qianjiang Yongan Pharmaceutical Co., Ltd. will invest a total of CNY 10 million for 5% in Wuhan Low-dimensional Materials Research Institute Co., Ltd. Post completion of both the transaction, Chang Haixin, Li Ganghui, Guo Hui, Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership) and Qianjiang Yongan Pharmaceutical Co., Ltd. will hold 35.98%, 0%, 17.63%, 6.40% and 40% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. respectively. As of December 31, 2020, Wuhan Low-dimensional Materials Research Institute Co., Ltd. reported total assets of CNY 29.44 million, net assets of CNY 11.6 million, revenue of CNY 0.01 million and net loss of CNY 10.86 million. The transaction was approved by the board of director of Qianjiang Yongan Pharmaceutical Co., Ltd. on the 24th meeting of the fifth board of directors held on April 30, 2021. The transaction do not need to be submitted to the shareholders meeting for deliberation.
Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership) on June 10, 2021. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥10.62, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total loss to shareholders of 31% over the past three years. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥10.90, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 38% over the past three years. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.027 (vs CN¥0.017 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥313.3m (up 43% from 1Q 2020). Net income: CN¥7.84m (up 59% from 1Q 2020). Profit margin: 2.5% (up from 2.3% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 19% per year. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥0.37 (vs CN¥0.31 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥1.17b (down 14% from FY 2019). Net income: CN¥105.6m (up 17% from FY 2019). Profit margin: 9.0% (up from 6.6% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Announcement • Feb 25
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report fiscal year 2020 results on Mar 31, 2021 Is New 90 Day High Low • Jan 28
New 90-day low: CN¥8.66 The company is down 16% from its price of CN¥10.32 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Jan 07
New 90-day low: CN¥9.00 The company is down 25% from its price of CN¥12.05 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: CN¥10.03 The company is down 17% from its price of CN¥12.02 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥10.32 The company is down 22% from its price of CN¥13.24 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥134.8m, up 40% from the prior year. Total revenue was CN¥1.25b over the last 12 months, down 2.8% from the prior year. Announcement • Oct 17
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report Q3, 2020 results on Oct 23, 2020 Is New 90 Day High Low • Oct 15
New 90-day low: CN¥11.10 The company is down 16% from its price of CN¥13.16 on 17 July 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Is New 90 Day High Low • Sep 28
New 90-day low: CN¥11.63 The company is down 4.0% from its price of CN¥12.11 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Announcement • Aug 11
Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020 
